Skip to main content
. Author manuscript; available in PMC: 2015 Mar 7.
Published in final edited form as: Cancer Res. 2014 Feb 24;74(8):2258–2269. doi: 10.1158/0008-5472.CAN-13-2459

Figure 1.

Figure 1

RSF1 expression and response to paclitaxel in patients with ovarian cancer and mouse xenograft models. A, expression level of RSF1 in patients with ovarian cancer in the CTCR-OV01 trial cohort. P values were determined by the Student t test. Horizontal lines, medians, boxes extend from the 25th to 75th percentiles, and error bars extend to the 10th and 90th percentiles. B, intratumoral administration of RSF1 shRNA (10 μg/kg) or control shRNA (Con shRNA; 10 μg/kg) was followed by intraperitoneal injections of paclitaxel (10 mg/kg) or same volume of vehicle. shRNA and paclitaxel were injected everyday for 14 days. Tumor sizes, relative mean volume ± SD. *, P < 0.05 compared with the vehicle treatment group with control shRNA. #, P < 0.05 compared with the paclitaxel treatment group with RSF1 shRNA.